News

BlogsPosts
As Seen In
RepliCel CEO: Anticipating the Approval of Their Dermal Injector, its Impact in Europe and Beyond
Click here to read the full article and interview as it appears
BlogsPosts
As Seen In
Japan is Fertile Ground for Biotech Deal
Click here to read the full article as it appears in the Streetwise Reports:
BlogsPosts
Press Release
RepliCel Life Sciences Successfully Closes Financing
Shareholders commit to non-brokered private placement in clear support of the Company’s partnership strategy
BlogsPosts
As Seen In
Company Uses Patients' Own Cells to Put an End to Baldness, Aging Skin and Tendon Degeneration
Company Uses Patients' Own Cells To Put An End To Baldness, Aging Skin And Tendon
BlogsPosts
As Seen In
Regenerative medicine: Interview with a game-changing leader
Regenerative medicine is a game-changing area of medicine. It has the potential to fully heal
BlogsPosts
Press Release
RepliCel’s Partnership Initiatives Mature into Licensing Negotiations
Due diligence and confidential discussions now moving into negotiations for products in both the tendon
BlogsPosts
Press Release
RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector
Delivery of RepliCel’s patented prototypes kick-starts functional testing, matures licensing discussions, and confirms commercialization schedule VANCOUVER,
BlogsPosts
As Seen In
Your Hair Follicles May Hold the Key to Younger Looking Skin
Click here to read the full article as
BlogsPosts
As Seen In
Analyst Says Cell Therapy Company’s Move Decreases Risk
Click here to read the full article as
BlogsPosts
Press Release
RepliCel Life Sciences Joins MedCision’s ThawSTAR® Early Adopter Program
Regenerative Medicine Company to Adopt ThawSTAR® Cell Thawing Systems to De-Risk Cell Therapy Clinical Trial VANCOUVER,
BlogsPosts
Press Release
Prominent Skin Aging Researcher Provides Insights into RepliCel’s Clinical Data
“We believe that this novel therapy has the potential to rejuvenate skin in a way
BlogsPosts
As Seen In
Skin in the Game
To read the full article as it appears on DDN News (08/08/17), click here.
BlogsPosts
As Seen In
Why RepliCel May Be the Most Compelling Biotech Company to Watch in Canada
To read the brief and watch the interview provided by Market One Media Group as
BlogsPosts
As Seen In
RepliCel Poised To Partner Up For Precision-Control Dermal Injector
To preview the interview with Tina Tan as it appears on Medtech.com, click here. (6/23/17)
BlogsPosts
As Seen In
Hair-Raising R&D: RepliCel Developing Autologous Cell Therapy for Baldness
To read the full article as it appears on BioPharma-reporter.com, click here. (7/12/17)
BlogsPosts
As Seen In
Poised for Success with Positive Clinical Results
To read the full interview as it appears on Costmeticosbr.com.br, click here (7/6/17).
BlogsPosts
As Seen In
A New Approach to Treating Hair Loss
To read the full interview as it appears on Technologyworks.com, click here. (6/27/17)
BlogsPosts
As Seen In
Your Hair Could Hold The Secret To Mending Your Injured Tendon
To read the full article as it appears on Pridenews.ca , click here
BlogsPosts
As Seen In
The Latest in Biocellular Regeneration
To read the full article as it appears on TheAestheticChannel.com by Lisette Hilton, click here
BlogsPosts
Press Release
RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map
Data from this project expected to take RepliCel’s products to next level of potential commercial

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.